Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Boosted by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 4,235 shares of the life sciences company’s stock after acquiring an additional 317 shares during the period. Azzad Asset Management Inc. ADV’s holdings in Illumina were worth $552,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Trivant Custom Portfolio Group LLC lifted its position in shares of Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after acquiring an additional 125 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after buying an additional 132 shares during the period. Industrial Alliance Investment Management Inc. purchased a new position in shares of Illumina in the second quarter worth approximately $34,000. Versant Capital Management Inc raised its holdings in shares of Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 246 shares during the period. Finally, Ables Iannone Moore & Associates Inc. purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $56,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Barclays upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price objective on the stock in a research report on Wednesday, August 14th. Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, July 10th. UBS Group increased their price objective on Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Daiwa America raised Illumina to a “strong-buy” rating in a research note on Friday, August 16th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $242.00 price target on shares of Illumina in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $152.05.

Illumina Stock Down 0.7 %

Illumina stock opened at $139.66 on Wednesday. The company has a market capitalization of $22.25 billion, a P/E ratio of -17.14 and a beta of 1.15. The firm’s fifty day simple moving average is $128.52 and its 200-day simple moving average is $120.45. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $148.19.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. Illumina’s revenue for the quarter was down 5.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 EPS. Sell-side analysts forecast that Illumina, Inc. will post 3.63 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.